Introduction: An estimated one hundred million African meningitis belt residents have received MenAfriVac
Introduction
Data also suggest that the vaccine is safe as delivered in the traditional cold chain. The MenAfriVac® package insert [7] and studies in India [8] and Mali [9] reported that the most common identified side effects at one week were pain at the injection site, diarrhea, loss of appetite, and fever.
On October 26, 2012, The Drugs Controller General of India (DCGI)
granted approval to license the vaccine for use in a controlled temperature chain (CTC) approach at temperatures of up to 40°C
for up to four days [7] , followed by WHO prequalification for this approach [10] . The CTC approach has the potential to reduce the logistical complexity of maintaining vaccines in the +2 to +8°C temperature range up to the moment of injection of the vaccine and thus increase vaccine access to remote areas [11] . Based on its review of available clinical trial safety data, the WHO Global Advisory Committee on Vaccine Safety concluded that MenAfriVac ® showed a favourable safety profile [12] . Ministry of Health (MoH) decided to pilot test the CTC approach, the first country globally to evaluate this approach. The present evaluation, integrated into a reinforced pharmacovigilance monitoring system, was designed to assess whether the vaccine delivered in the CTC approach resulted in unexpected AEFIs. Due to logistical and budget constraints, we did not attempt to detect rare (0.1-0.01%) or very rare events (<0.01%) or benign effects that have not been described previously in the literature.
Methods
Ethical issues: the Drugs Controller General of India (DCGI) granted approval to license the vaccine for use in a CTC approach.
The Benin MoH determined that the current activities did not require institutional review board approval based on a) use of an on-label approach and b) its assessment that the decision to implement and conduct a quality control evaluation of the CTC approach fell within its public health authority as part of routine immunization activities Household survey data were collected on five consecutive days starting the day following the vaccination day for villages where the campaign lasted a single day, and two days after the first vaccination day in villages where the campaign lasted several days.
We included only a 5-day evaluation period because studies have found no evidence for AEFIs beyond 4 days after vaccination.
Additionally, five days limited the possibility of recall bias. Role of the funder: the funder provided technical input into the study interpretation and draft manuscript but had no editorial control over the final manuscript contents. Christoph Steffen had full access to the study data and along with the Benin MoH made the final decision to submit for publication.
Results
As measured at the Kandi weather station, temperatures ranged from 19 to 46°C during the vaccination period. A total of 1000 participants were included in the CTC and 999 in the non-CTC group. The CTC group used lot number 127M1045 and the non-CTC group lot number 127M1047. Details on site characteristics are found in Table 1 . Eighteen persons had missing information for sex, and nine had missing information for age. For pregnancy and breastfeeding status, respectively, 543 and 539 women had missing values because investigators assumed wrongly that only positive status should be reported. We assumed in our analysis that all women where information on pregnancy or breast-feeding status was missing, were not pregnant or not breast-feeding ( Table 2 ).
The total person-days of follow-up was 3140 in the CTC and 2818 in the non-CTC group. The mean duration between immunisation and interview was 3.1 days in the CTC group and 2.8 days in the non-CTC group (p<0.05) ( In our setting, the actual exposure duration usually was much shorter, with a mean of 20 hours, and none of the exposures exceeded the recommended limit even if this limit was approached.
Additionally, we did not see evidence for increased fever or other outcomes as exposure duration increased. These data confirm the practicality of the CTC approach, including that the exposure duration limit in the package insert is likely to be sufficient to achieve objectives during a campaign setting.
Limitations: Our evaluation had several limitations related firstly to
it being a public health intervention under real-life conditions rather than a study and secondly to its development and implementation within three weeks to meet the MenAfriVac 
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